The pharmaceutical industry is full currently, self-confidence. Despite criticism from President Donald Trump, several manufacturers in the United States have increased since the beginning of the year, the prices of medications. With the money you can afford billions more Acquisitions.
The "pharmaceutical of the year" has started with a Bang. For about 74 billion dollars of the US group swallows Bristol-Myers Squibb, the Biotech company Celgene. It is one of the largest pharmaceutical Deals in history. As early as 2018, the Japanese drug manufacturer Takeda had swallowed for $ 59 billion to the Irish rival Shire.
No wonder that "Big Pharma" is currently in the money. The industry giants such as Pfizer and Merck & Co are sitting on Cash reserves of more than ten billion dollars.price increases of over six percent
this year, a new revenue wave. In the USA, with a share of 41 percent of the most important pharmaceutical market in the world, have increased at the beginning of January, the pharmaceutical company, many of their products by an average of 6.3 per cent, calculated by the Software service provider, RX Saving Solutions in a study. Especially Allergan turned sharply screw on the price. More than half of the Allergan products more expensive. Also, Bayer increased the prices of six drugs.
for More course information, Pfizer
Additional course Additional course information to Allergan
information about Bayer
pioneer industry leader Pfizer. Already in November of the Viagra, announced manufacturer price increases for 41 medicines for this year. In mid-July, Pfizer had delayed a price boost after a US President, Trump had intervened. "Pfizer and others should be ashamed that they have increased the drug prices without reason," he tweeted angrily. And threatened the industry with the words: "We will respond!"
Shortly before the mid-term elections Trump announced a Plan to reduce drug prices. The project will be considered but only for medicines that are issued at the doctor's office. Not drugs sold in pharmacies are concerned.Trump with the pharmaceutical industry
Trump accuses the pharmaceutical industry, to generate at the expense of the US taxpayer a fortune. It was unfair that the Americans paid for the same drug, significantly more than patients in other countries, he explained. Probably almost nowhere in the world the drugs are as expensive as in the USA. The average American has to shell out per year to 1,100 dollars for pills and other drugs - more than Double what the average Briton spends (497 dollars).
in fact, the pharmaceutical companies have in the US a lot of freedom in pricing. Unlike in Germany or in Switzerland, there is no Central state authority, which controls the prices of the authorisation of a preparation.
Pfizer boss Ian Read
to blame for the high prices are not the manufacturer, but the health insurance, increase the deductible, says Pfizer CEO Ian Read. In addition, it was the drugs prices to list prices. It often give discounts. The effect of price increases on sales is likely to be thus limited.in the long term, prices could drop
the reasoning of The Pfizer-heads can't appease Donald Trump. The US President fights undauntedly against the pharmaceutical lobby. He expect that it will come to courses massive Price in this year, he said at the beginning of January. Analysts see, in the meantime, the price debate in the United States as one of the major risks for the pharmaceutical industry. Experts of the Bank HSBC has predicted recently that by 2030 it is expected to fall the pharmaceutical prices in the United States by 30 percent compared to the level of today.
Nor is it about "Big Pharma" is quite good. The manufacturers are bringing more and more drugs on the market. In the past year alone has been achieved in the USA, with 59 registrations for new substances, a record.
in 2018, should the 15 leading companies have increased sales worldwide by an average of 2.6 per cent to around 550 billion dollars, estimates the data service Bloomberg. For this year analysts expect a Plus of 2.7 percent.industry> consolidated
Siegfried Bialojan, a pharmaceutical expert at the consulting firm EY, can imagine more big Acquisitions this year. Especially in the case of new therapies such as T-cells, stem cells, or the novel gene therapies using Crispr classic pharmaceutical manufacturers are not placed so well, he said in the "süddeutsche Zeitung".Crispr as a new driver of innovation?
Peer Schatz, chief of the Biotech company Qiagen, raves of Crispr as a "next technology revolution". With the Genschere Crispr/Cas9, scientists can delete parts of the genome and replace it. This may cause diseases such as Malaria and severe genetic diseases such as cystic fibrosis or muscular dystrophy prevent.
Further course information, to Qiagen
The persistent Fusionitis could provide to the stock exchange for the new fantasy. 2018 pharmaceutical shares were among the big winners on Wall Street. The papers of Pfizer rose to A one-year term, to around 20 percent, the title of Merck & Co rose in the same period, even by almost 30 percent.
More rates achieved information to Merck & co.source: boerse.ard.de Tough, Sartorius its objectives Philips positively surprised